<DOC>
	<DOCNO>NCT02260882</DOCNO>
	<brief_summary>The purpose study determine revaccination pneumococcal vaccine ( PNEUMOVAX™ 23 , V110 ) well tolerated produce immune response old Japanese adult . The primary hypothesis test geometric mean concentration antibody pneumococcal polysaccharide serotypes 3 , 6B , 23F 4 week revaccination superior revaccination Japanese adult receive primary vaccination least 5 year revaccination .</brief_summary>
	<brief_title>Revaccination With PNEUMOVAX™ 23 Older Japanese Adults ( V110-902 )</brief_title>
	<detailed_description />
	<mesh_term>Pneumococcal Infections</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<mesh_term>Heptavalent Pneumococcal Conjugate Vaccine</mesh_term>
	<criteria>Japanese participant Good health underlie chronic illness document stable condition Revaccination Group : receive one document PNEUMOVAX™ 23 vaccination least 5 year enrollment study Primary Vaccination Group : prior history PNEUMOVAX™ 23 vaccination Exclusion Criteria : Known allergy sensitivity component study vaccine History pneumococcal conjugate vaccination Known suspect immune dysfunction , immunosuppression , autoimmune disease . Participants history cancer actively treat immunosuppressed eligible Functional anatomic asplenia Received immunoglobulin within 6 month study vaccine plan study Received investigational drug vaccine within 2 month study vaccination History pneumococcal disease ( positive culture blood normally sterile site ) Thrombocytopenia coagulation disorder would contraindicate intramuscular injection History convulsion Previously diagnose immunodeficiency close relative congenital immune deficiency Participating clinical trial</criteria>
	<gender>All</gender>
	<minimum_age>70 Years</minimum_age>
	<maximum_age>89 Years</maximum_age>
	<verification_date>July 2016</verification_date>
</DOC>